Bharat Parenterals has issued a corrigendum to the notice for its Extraordinary General Meeting (EGM) scheduled for October 23, 2026. The revision introduces mandatory disclosures regarding the appointment of a monitoring agency for its proposed preferential issue of equity shares.

The company filed an application with BSE Limited seeking in-principle approval for the preferential issue. Following this, BSE directed Bharat Parenterals to provide additional details on the monitoring agency arrangement. Consequently, the company inserted a new paragraph into the explanatory statement for Item No. 1 of the EGM notice.

Monitoring Agency Appointment

The corrigendum specifies that because the issue size exceeds ₹100 crore, the company is required under Regulation 162A of the SEBI ICDR Regulations to appoint a SEBI-registered credit rating agency as the monitoring agency. This agency will oversee the utilization of proceeds from the preferential issue.

Bharat Parenterals has appointed Crisil Ratings Limited, a SEBI-registered credit rating agency, to serve in this capacity. This step ensures compliance with regulatory norms governing large-scale capital raises through preferential allotments.

Regulatory Compliance and Next Steps

The original EGM notice was dispatched to members in compliance with the Companies Act, 2013, and SEBI circulars. The new corrigendum is deemed an integral part of the original notice and must be read in conjunction with it. All other particulars and details mentioned in the initial EGM notice remain unchanged.

Shareholders are advised to review the updated explanatory statement before voting on the preferential issue resolution during the virtual meeting scheduled for Friday, October 23, 2026, at 11:30 am.

Bharat Parenterals Limited has scheduled an Extra-Ordinary General Meeting (EGM) for Friday, October 23, 2026, to seek shareholder approval for a ₹139 crore preferential issue of equity shares. The meeting will be held via Video Conference (VC) and Other Audio-Visual Means (OAVM).

The allotment is proposed for 15 identified investors at a price of ₹1,522.85 per share. This follows the board meeting convened on Tuesday, September 29, 2026, where the feasibility and terms of the capital raise were evaluated and finalized.

EGM Details and Voting Schedule

The EGM is scheduled to commence at 11:30 am IST on October 23, 2026. Remote e-voting will commence on Tuesday, October 20, 2026, at 9:00 am IST and conclude on Thursday, October 22, 2026, at 5:00 pm IST. The cut-off date for e-voting eligibility is Friday, October 16, 2026.

Members may participate in the meeting through the NSDL e-voting platform. The company has appointed Jigar Trivedi & Co, Practicing Company Secretaries, as the scrutinizer for the voting process.

Board Meeting Agenda and Objectives

The primary agenda of the September 29 meeting was to consider and approve the preferential issue. The board assessed the proposal's viability before granting approval. The special resolution seeks approval to create, offer, issue, and allot up to 9,12,759 equity shares to non-promoter allottees.

The proceeds from the issue are intended for:

• Investment in Subsidiaries: Up to ₹135 crore for funding existing and proposed business activities, expansion plans, and capital expenditure of subsidiaries including Varenyam Biolifesciences Private Limited, Varenyam Healthcare Private Limited, and Innoxel Lifesciences Private Limited.
• General Corporate Purposes: Up to ₹3.99 crore for expenses towards the preferential issue and other operational requirements.

Pricing and Allottees

The issue price of ₹1,522.85 per share includes a premium of ₹1,512.85. This price was determined based on a valuation report by Bhari Lal Chakravarti, Chartered Accountants, which derived a value of ₹1,518.00 per share. The floor price certificate issued by M/s. Jigar Trivedi & Co confirms the compliance with SEBI ICDR regulations.

Key proposed allottees include Whiteoak Capital India Opportunities Fund (₹46 crore), Aurum Rising India Fund (₹25 crore), and Whiteoak Capital Equity Trust (₹20 crore). Other participants include Ashoka India Equity Investment Trust PLC and various other AIFs and mutual funds.

Additional Resolution on Section 186 Limits

The EGM will also consider a special resolution to approve investments, loans, guarantees, and securities in excess of limits specified under Section 186(2) of the Companies Act, 2013. The company seeks approval to exceed the statutory limit by an aggregate sum of ₹140 crore, over and above the prescribed thresholds, to facilitate long-term business plans and group funding needs.

Trading Window Closure

In compliance with the company's Code of Conduct for regulating trading by designated persons, the trading window for dealing in Bharat Parenterals securities remains closed. The closure began on September 24, 2026, and will continue until 48 hours after the conclusion of the board meeting.

Regulatory Compliance

The intimation regarding the board meeting and subsequent approvals was filed under Regulation 29 and Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice is available on the company's website and the BSE portal for public record.